James J Harding, Robin K Kelley, Benjamin Tan, Marinela Capanu, Gian Kinh Do, Jinru Shia, Joanne F Chou, Christine S Ferrer, Chayma Boussayoud, Kerri Muenkel, Hooman Yarmohammadi, Imane El Dika, Danny N Khalil, Carmen Ruiz, Mariam Rodriguez Lee, Peter Kuhn, John Wilton, Renuka Iyer, Ghassan K Abou-Alfa
LESSONS LEARNED: Androgen receptor as assessed by immunohistochemistry is expressed in a high proportion of patients with hepatocellular carcinoma (HCC). Enzalutamide at 160 mg orally daily is safe and tolerable in patients with advanced HCC but has no single-agent antitumor activity. Enzalutamide, a CYP3A4 inducer, at a standard dose of 160 mg reduces the exposure of sorafenib, a CYP3A4 substrate. Enzalutamide and sorafenib is safe and tolerable in patients with advanced HCC, but the addition of enzalutamide to sorafenib did not enhance the antitumor activity of sorafenib...
June 16, 2020: Oncologist